Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Bezafibrate; Ezetimibe; Fenofibrate
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY-NIPPON
- Sponsors Sanofi
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 09 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.
- 20 Apr 2017 Planned End Date changed from 1 Mar 2018 to 1 Jan 2018.